Doxepin cream relieves eczema-associated pruritus within 15 minutes and is not accompanied by a risk of rebound upon discontinuation

Journal of Dermatological Treatment

Volumn 8, Issue 3, 1997, Pages 161-168

  Breneman, D L ^a   Dunlap, F E ^b   Monroe, E W ^c   Schupbach, C W ^d   Shmunes, E ^e   Phillips, S B ^f,g  

^a University Dermatology Consultants   (United States)

^b Argus Research Inc   (United States)

^c Advanced Healthcare   (United States)

^d Mecklenburg Clinical Research Inc   (United States)

^e Columbia Skin Clinic ^*  (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Atopic dermatitis; Clinical investigation; Doxepin; Eczema; Therapy

Indexed keywords

ANTIPRURITIC AGENT; DOXEPIN;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SOMNOLENCE; TOPICAL DRUG ADMINISTRATION; XEROSTOMIA;

EID: 0030798511     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.3109/09546639709160512     Document Type: Article

References (31)

1. Hanifin JM, Atopic dermatitis. In: Middleton E Jr, Reed CE, Ellis EF et al (eds) Allergy principles and practice, 4th edn. Mosby: St. Louis, 1993, pp 1581-604.
2. Greaves MW, Pathophysiology and clinical aspects of pruritus. In: Fitzpatrick TB, Eisen AZ, Wolff K. Freedberg IM, Austen KF (eds) Dermatology in general medicine, 4th edn. McGraw-Hill: New York, 1994, pp 413-21.
3. Hanifin JM, Rajka G, Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) (1980) 92: 44-7.
4. Sampson HA, Atopic dermatitis. Ann Allergy (1992) 69: 469-79.
5. Bernhard JD, Scratching. In: Bernhard JD (ed) Itch: mechanisms and management of pruritus. McGraw-Hill: New York, 1994, pp 97-102.
6. Wahlgren CF, Pathophysiology of itching in urticaria and atopic dermatitis. Allergy (1992) 47: 65-75.
7. Behrendt H, Ring J, Histamine, antihistamines and atopic eczema. Clin Exp Allergy (1990) 20 (Suppl 4): 25-30.
8. Mihm MC Jr, Soter NA, Dvorak HF et al, The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol (1976) 67: 305-12.
9. Wahlgren CF, Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol Suppl (Stockh) (1991) 165: 1-53.
10. Drake LA, Fallon JD, Sober A et al, Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol (1994) 31: 613-16.
11. Drake LA, Millikan LE, Doxepin Study Group, The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Arch Dermatol (1995) 131: 1403-8.
12. Millikan LE, Treating pruritus. Postgrad Med (1996) 99: 173-84.
13. Wahlgren CF, Hagermark O, Bergstrom R, The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol (1990) 122: 545-51.
14. Berth-Jones J, Graham-Brown RAC, Failure of terfenadine in relieving the pruritus of atopic dermatitis. Br J Dermatol (1989) 121: 635-7.
15. Richelson E, Antimuscarinic and other receptor-blocking properties of antidepressants. Mayo Clin Proc (1983) 58: 40-6.
16. Goldsobel AB, Rohr AS, Siegel SC et al, Efficacy of doxepin in the treatment of idiopathic urticaria. J Allergy Clin Immunol (1986) 78: 867-73.
17. Neittaamnaki H, Fraki JE, Combination of localized heat urticaria and cold urticaria: release of histamine in suction blisters and successful treatment of heat urticaria with doxepin. Clin Exp Dermatol (1988) 13: 87-91.
18. Figueiredo A, Fontes-Ribeiro CA, GonCalo M et al, Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol (1990) 4: 147-58.
19. Bernstein JE, Whitney DH, Soltani K, Inhibition of histamine-induced pruritus by topical tricyclic antidepressants. J Am Acad Dermatol (1981) 5: 582-5.
20. Bernstein JE, Gillenwater GE, Relief of eczema-associated pruritus by doxepin hydrochloride. J Invest Dermatol (1986) 86: 463.
21. Tortora GJ, Anagnostakos NP, The integumentary system. In: Principles of anatomy and physiology, 3rd edn. Harper & Row. New York, 1981, p 116.
22. Wahlgren CF, Hagermark O, Bergstrom R et al, Evaluation of a new method of assessing pruritus and antipruritic drugs. Skin Pharmacol (1988) 1: 3-13.
23. Fleiss JL, The design and analysis of clinical experiments. John Wiley: New York, 1986.
24. Simone DA, Alreja M, LaMotte RH, Psychophysical studies of the itch sensation and itchy skin ('allokinesis') produced by intracutaneous injection of histamine. Somatosens Most Res (1991) 8: 271-329.
25. Meyer RA, Campbell JN, A novel electrophysiological technique for locating cutaneous nociceptive and chemospecific receptors. Brain Res (1988) 441: 81-6.
26. LaMotte RH, Simone DA, Baumann TK et al, Hypothesis of novel classes of chemoreceptors mediating chemogenic pain and itch. In: Dubner R, Gebhart GF, Bond MR (eds) Procedings of the Vth World Congress on Pain. Elsevier Science Publishers: New York, 1988, pp 529-35.
27. Shelley WB, Arthur RP, The neurohistology and neurophysiology of the itch sensation in man. Arch Dermatol (1957) 76: 296-323.
28. Johansson O, Hilliges M, Stahle-Backdahl M, Intraepidermal neuronspecific enolase (NSE)-immunoreactive nerve fibres: evidence for sprouting in uremic patients on maintenance hemodialysis. Neurosci Lett (1989) 99: 281-6.
29. Wang L, Hilliges M, Jemberg T et al, Protein gene product 9.5-immunoreactive nerve fibres and cells in human skin. Cell Tissue Res (1990) 261: 25-33.
30. Zonalon cream (doxepin hydrochloride cream), 5%: a clinical review. GenDerm Corporation: Lincolnshire, Ill, 1994, pp 13-14.
31. Shelanski MV, Phillips SB, Potts CE, Evaluation of cutaneous reactivity to recently marketed dermatologie products. Int J Dermatol (1996) 35: 137-40.